Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 736.80

-1.4%

12:04 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (698)	10/31/2002 8:02:51 PM
From: Miljenko Zuanic	Read Replies (2) of 3559

Problems with PEG-A formulation? Is this related to physico-chemical nature of all components in formulation, or related to bio-chemical nature of the PEG fragment(s)? Who knows what is going on with oral A formulation? Anyway, based on dropout rate so far, appears to me that many pts (about 50% did completed one year blind period) did enter one year extension period. Also, so far they are very serious about A manufacturing, which may (or may not?) indicate internal confidence. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next